FDA approves neladalkib for ALK-positive lung cancer - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves neladalkib for ALK-positive lung cancer

  • By

  • Teraya Smith

  • November 18, 2026

  • 2 min

Share

Clinical Scorecard: FDA approves neladalkib for ALK-positive lung cancer

At a Glance

CategoryDetail
ConditionLocally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC)
Key MechanismsNeladalkib is an oral ALK tyrosine kinase inhibitor; the source does not describe its mechanism in further detail.
Target PopulationAdults previously treated with alectinib as their only ALK TKI in the unresectable locally advanced or metastatic setting, or with at least 2 ALK TKIs and platinum-based chemotherapy.
Care SettingTreatment of adults with locally advanced or metastatic ALK-positive NSCLC after prior targeted therapy.

Key Highlights

  • The FDA granted accelerated approval to neladalkib on November 17.
  • In ALKOVE-1, confirmed overall response rate was 49% among 67 patients previously treated with alectinib as their only ALK TKI.
  • In a separate group of 155 patients previously treated with at least 2 ALK TKIs and platinum-based chemotherapy, confirmed overall response rate was 32%.
  • The trial was multicenter, single-arm, and open-label, with no randomized comparator group.
  • Neladalkib is taken orally at 150 mg once daily, with or without food, until disease progression or unacceptable toxicity.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Safety warnings include hepatotoxicity, renal toxicity, ocular toxicity, elevated creatine phosphokinase levels, and embryo-fetal toxicity.

      Risks

        Patient & Prescribing Data

        Adults with locally advanced or metastatic ALK-positive NSCLC previously treated either with alectinib as their only ALK TKI in the unresectable locally advanced or metastatic setting, or with at least 2 ALK TKIs and platinum-based chemotherapy.

        In ALKOVE-1, response rates were 49% and 32% in the respective prior-treatment groups. Among responders, 76% and 69% maintained response for at least 6 months, and 52% and 51% maintained response for at least 12 months.

        Clinical Best Practices

        • Neladalkib is administered orally at 150 mg once daily, with or without food, until disease progression or unacceptable toxicity.
        • Safety warnings include hepatotoxicity, renal toxicity, ocular toxicity, elevated creatine phosphokinase levels, and embryo-fetal toxicity.

        Related Resources & Content

        Original Source(s)

        Related Content